Evidence map›Paper›PMID 42415719›Full record

ArticleEJHaem2026

Immune Effector Cell-Associated Hematotoxicity With Secondary Myelofibrosis Following Idecabtagene-Vicleucel for Multiple Myeloma, Comprehensively Treated With Autologous Hematopoietic Stem Cell Boosting.

Keishi Ogura, Takahiro Fujino, Takahisa Nakamura, Akihiro Miyashita, Akio Onishi, Taku Tsukamoto, Shinsuke Mizutani, Yuji Shimura, Shinichi Fuchida, Junya Kuroda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keishi OguraDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Takahiro FujinoDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Takahisa NakamuraDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Akihiro MiyashitaDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Akio OnishiDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Taku TsukamotoDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Shinsuke MizutaniDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Yuji ShimuraDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.
Shinichi FuchidaDepartment of Hematology Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center Kyoto Japan.
Junya KurodaDivision of Hematology and Oncology Department of Medicine Kyoto Prefectural University of Medicine Kyoto Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancytopenia accompanied by chimeric antigen receptor T cell (CAR-T) therapy is termed immune effector cell-associated hematopoietic toxicity (ICAHT), which is often sustained and refractory to supportive care. We report a case of a 52-year-old man with multiple myeloma who developed severe ICAHT with secondary myelofibrosis (sMF) after administration of idecabtagene-vicleucel, which was comprehensively improved by autologous hematopoietic stem cell boosting. This case focuses on sMF as a rare but cautionary complication of CAR-T therapy, underscoring the importance of bone marrow biopsy to exclude sMF and of stem cell boosting for the treatment of persistent ICAHT.

Indexed as

autologous hematopoietic stem cell boostingchimeric antigen receptor T cell (CAR‐T) therapyimmune effector cell‐associated hematopoietic toxicitymultiple myelomasecondary myelofibrosis

Identifiers

PMID42415719
PMCPMC13338105

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.